Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization
- PMID: 30863166
- PMCID: PMC6388942
- DOI: 10.2147/CMAR.S189025
Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization
Abstract
Background: Near-triploidy/tetraploidy is rarely found in acute leukemia. Only limited data are available to characterize this condition, and it remains largely unknown.
Patients and methods: In our study, we performed karyotype analysis on 1,031 patients diagnosed with acute leukemia from 2006 to 2018. A total of 10 patients of near-triploidy/tetraploidy karyotype were enrolled. Two cases of near-triploidy (66-79 chromosomes) and eight cases of near-tetraploidy (84-100 chromosomes) were identified. Bone marrow samples of these 10 patients were analyzed by fluorescence in situ hybridization with 19 commercially available probes that detected a small portion of gene alterations and large regions of chromosome amplifications.
Results: Of the six patients with acute myelocytic leukemia, we detected three cases of double t(8;21)(q22;q22) that have not been previously reported, and one of them demonstrated ins(21;8) (q22;q24q22). We also describe a novel pediatric case carrying double t(15;17)(q22;q21) and receiving targeted treatment with all-trans retinoic acid therapy. To date, this case has responded well to the regimen and has shown continuous complete remission. All patients received chemotherapy. One of them received allogeneic hematopoietic stem cell transplant (HSCT) and survived for 22 months. Eight of the 10 patients died, and the median overall survival was 11 months.
Conclusion: Using fluorescence in situ hybridization, we identified the distinct complex karyotype of near-triploidy/tetraploidy and provided further prognostic information. Tetraploidy acute promyelocytic leukemia had favorable prognosis; thus, HSCT was not necessary. The case of insertion t(21;8)(q22;q24q22) in tetraploidy responded poorly to chemotherapy and achieved molecular remission with difficultly. Data from patients in this group indicated that near-triploidy/tetraploidy acute leukemia has poor prognosis and new therapy is urgently needed.
Keywords: acute leukemia; fluorescence in situ hybridization; gene; near-triploidy; tetraploidy karyotype.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures




References
-
- Mkrtchyan H, Garcia Ney DR, de Ventura ES, et al. Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2010;197(1):71–74. - PubMed
-
- Li L, Li J, Li G, et al. A tetraploid minimally differentiated acute myeloblastic leukemia with extensive erythrophagocytosis: a case report and literature review. Int J Hematol. 2012;96(6):801–805. - PubMed
-
- Berbari B, Behrens ME, Hathaway LJ. Tetraploidy in acute myeloid leukemia is associated with poor outcomes regardless of the presence of favorable risk features, and requires an allogeneic stem cell transplant in first remission. Blood. 2017;130
-
- Mühlbacher V, Zenger M, Schnittger S, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% Genes Chromosomes Cancer. 2014;53(6):524–536. - PubMed
-
- Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECoG) 2993 trial. Blood. 2007;109(8):3189–3197. - PubMed
LinkOut - more resources
Full Text Sources